RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Gfp, of the three summary posts you provided, I think the first two together constitute a very solid appraisal of the current situation. At least on first look, I have little or nothing to add. I don't agree entirely with the third segment.

Not that SA isn't critical, indeed it may be that RD has become melded with it in the eyes of some if not all prospective partners, which raises some of the complications you noted. But if SA fails, Plan C IMHO would be to try to partner CX1739/ADHD for ex-US use. The terms would not be great, but they could probably get enough to run that pilot trial in ADHD. If that was successful, then they would have the US rights to partner on better terms--perhaps the EU partner would have a right of first refusal with preset better upfronts.

Blade: Regarding virtual company resurrections; I know lots of private companies that are existing in near-virtual mode. But but I take it that your question pertains to companies which have shrunken back into virtual mode and, to some degree, hibernated while events unfolded out of their hands. The closest example I can think of might be Cypress Biosciences, which went through some early problems/failures, before I followed them--then licensed milnacipran, which they then licensed to Forest. While Forest did the Phase III trials for milnacipran in fibromyalgia, Cypress was down to around 12 staff, looking at licensing, kicking the tires on a few possibilities, but really just waiting for Forest's trials to be completed. There are plenty of differences in terms of cash on hand (they had to use some of their upfront money to help pay trial expenses), level of program development, but I can't think of anything more relevant--and this isn't very relevant. I'm not sure the virtual model (I don't know exactly how Garren defines it) would apply to Cortex anyways--though they are already close to virtual,albeit they are running the trial(s) that will determine their fate.

NeuroInvestment